To study the expression of estrogen, progesterone receptor and p53 immunohistochemistry markers in subtyping endometrial carcinoma
Indian Journal of Pathology and Microbiology · 2024
DOI: 10.4103/ijpm.ijpm_568_22 ↗Kurz gefasst
Fachartikel in der Zeitschrift Indian Journal of Pathology and Microbiology, 2024. Verfasst von Anuja Yadav und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Apollo Hospitals, Jubilee Hills, Hyderabad, Andhra Pradesh, India. Hauptthemen laut MEDLINE: Carcinoma, Endometrioid, Endometrial Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 26 Literaturangaben.
Abstract (Originalsprache)
Background
Endometrial cancer is one of the most commonly diagnosed cancers in women worldwide. Aim and Objectives: To study the expression of estrogen receptor (ER), progesterone receptor (PR) and p53 immunohistochemistry (IHC) markers in subtyping endometrial carcinoma. Materials and Methods: A total of 100 cases of carcinoma endometrium submitted during January 2016 to October 2018 were included in our study. The ER, PR and p53 expressions were scored as per the adopted scoring system. Agreement between ER, PR and p53 IHC expression and the consensus HE diagnosis, FIGO grading and tumour staging were assessed using Chi square tests.
Results
There was a statistical association between ER, PR and p53 status and tumour histologic type with a P value < 0.01. There was no statistical significance observed between ER and PR expressions and different FIGO grades. Statistical significance (P = 0.036) between p53 and different FIGO grades seen. No statistical significance was observed between ER, PR and p53 expressions and different tumour stages and tumour invasiveness. There was a statistical association between ER and PR status and lymph node metastasis. p53 did not show a statistical significance.
Conclusion
Combination of ER, PR and p53 IHC markers can be used to distinguish type 1 and type 2 endometrial cancers. PR expression is more specific than ER in endometrioid carcinomas. p53 expression is more specific in serous carcinoma, however, p53 IHC alone cannot be used to distinguish different grades of endometrioid carcinomas as there is variability of staining in endometrioid carcinomas.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology, Apollo Hospitals, Jubilee Hills, Hyderabad, Andhra Pradesh, India.
- Department of Surgical Oncology, Apollo Hospitals, Jubilee Hills, Hyderabad, Andhra Pradesh, India.
Zitieren
APA
Yadav, A., Sistla, A., Swain, M., Gowrishankar, S., Padua, M., Modi, T., Himabindu, R., Agarwal, N., Kulkarni, A., Bhandari, T., Vudayaraju, H., Chinnababu, & Reddy, V. A. (2024). To study the expression of estrogen, progesterone receptor and p53 immunohistochemistry markers in subtyping endometrial carcinoma. Indian Journal of Pathology and Microbiology. https://doi.org/10.4103/ijpm.ijpm_568_22
Vancouver
Yadav A, Sistla A, Swain M, Gowrishankar S, Padua M, Modi T, et al. To study the expression of estrogen, progesterone receptor and p53 immunohistochemistry markers in subtyping endometrial carcinoma. Indian Journal of Pathology and Microbiology. 2024. doi:10.4103/ijpm.ijpm_568_22
BibTeX
@article{Yadav2024,
author = {Yadav, Anuja and Sistla, Anuradha and Swain, Meenakshi and Gowrishankar, Swarnalata and Padua, Michelle de and Modi, Tejal and Himabindu, Rallabandi and Agarwal, Neha and Kulkarni, Aditya and Bhandari, Trilok and Vudayaraju, Hemanth and Chinnababu and Reddy, Vijay A},
title = {To study the expression of estrogen, progesterone receptor and p53 immunohistochemistry markers in subtyping endometrial carcinoma},
journal = {Indian Journal of Pathology and Microbiology},
year = {2024},
doi = {10.4103/ijpm.ijpm_568_22}
}
EUVIMED